Duman Sanem Coşkun, Özkan Esra, Özdemir Yasemin Gürsoy
Neuroscience Research Lab, Research Center for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey.
Department of Neurology, School of Medicine, Koç University, Istanbul, Turkey.
Noro Psikiyatr Ars. 2023 Aug 12;60(3):292-294. doi: 10.29399/npa.28266. eCollection 2023.
Many researches have shown that coronavirus infection can lead to neurological symptoms. The most common symptom is headache. Calcitonin gene-related peptide (CGRP), which has an important role in the pathophysiology of migraine, may have an active role in persistent headaches after COVID, due to the structural similarity between the CGRP receptor and the SARS-CoV-2 spike protein. In this case report, the effect of the anti-CGRP monoclonal antibody on the migraine attack occurring after COVID-19 m-RNA vaccine will be discussed. A 55-year-old female patient who is followed up with a diagnosis of chronic migraine, had severe and throbbing headache that started after the COVID-19 m-RNA vaccine. After galcanezumab (CGRP monoclonal antibody - CGRP mAb) was started in the patient whose complaints did not regress despite the adjustment of the current drug doses, clinically significant improvement was observed in her complaints after the first dose and it was planned to continue with 120 mg CGRP mAb per month in her follow-ups.
许多研究表明，冠状病毒感染可导致神经症状。最常见的症状是头痛。降钙素基因相关肽（CGRP）在偏头痛的病理生理学中起重要作用，由于CGRP受体与SARS-CoV-2刺突蛋白之间的结构相似性，CGRP可能在新冠感染后的持续性头痛中发挥积极作用。在本病例报告中，将讨论抗CGRP单克隆抗体对新冠mRNA疫苗接种后发生的偏头痛发作的影响。一名55岁女性患者，诊断为慢性偏头痛，在接种新冠mRNA疫苗后出现严重搏动性头痛。在调整当前药物剂量后症状仍未缓解的患者中开始使用加卡尼单抗（CGRP单克隆抗体 - CGRP mAb），首剂后观察到其症状有显著临床改善，后续计划每月继续使用120mg CGRP mAb进行治疗。
